These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 17048975

  • 1. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF.
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [Abstract] [Full Text] [Related]

  • 2. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
    Kearney BP, Ramanathan S, Cheng AK, Ebrahimi R, Shah J.
    J Clin Pharmacol; 2005 Aug; 45(8):935-40. PubMed ID: 16027404
    [Abstract] [Full Text] [Related]

  • 3. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
    Kearney BP, Flaherty JF, Shah J.
    Clin Pharmacokinet; 2004 Aug; 43(9):595-612. PubMed ID: 15217303
    [Abstract] [Full Text] [Related]

  • 4. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV.
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Adolescent Trials Network for HIV/AIDS Interventions.
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tenofovir disoproxil fumarate for the treatment of HIV infection.
    Pham PA, Gallant JE.
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB, Stone EA, Piacenti FJ.
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [Abstract] [Full Text] [Related]

  • 11. Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.
    Lu C, Jia Y, Yang J, Song Y, Liu W, Ding Y, Sun X, Wen A.
    Clin Drug Investig; 2012 May 01; 32(5):333-8. PubMed ID: 22413748
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.
    Hu CY, Liu YM, Liu Y, Chen Q, Wang W, Wu K, Dong J, Li J, Jia JY, Lu C, Sun SX, Yu C, Li X.
    Clin Ther; 2013 Dec 01; 35(12):1884-9. PubMed ID: 24148552
    [Abstract] [Full Text] [Related]

  • 14. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
    Adusumilli S.
    Drugs Today (Barc); 2009 Sep 01; 45(9):679-85. PubMed ID: 19956809
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA.
    J Antimicrob Chemother; 2014 May 01; 69(5):1362-9. PubMed ID: 24508897
    [Abstract] [Full Text] [Related]

  • 16. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN, Schöller-Gyüre M, De Smedt G, Beets G, Aharchi F, Peeters MP, Vandermeulen K, Woodfall BJ, Hoetelmans RM.
    HIV Med; 2009 Mar 01; 10(3):173-81. PubMed ID: 19207601
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Droste JA, Kearney BP, Hekster YA, Burger DM.
    J Acquir Immune Defic Syndr; 2006 Jan 01; 41(1):37-43. PubMed ID: 16340471
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.